- Avivagen (VIV) will supply 660 kg of OxC-beta to a dairy supplier in Mexico
- OxC-beta is a non-antibiotic alternative for livestock feeds to support immune function and promote health and growth
- The customer will receive the order in 220 kg monthly instalments beginning next month
- Avivagen develops products for human and animal applications that support immune function and promote general health and performance
- Avivagen (VIV) is down by 5.71 per cent trading at $0.165 per share
Avivagen (VIV) will supply 660 kg of OxC-beta to a dairy supplier in Mexico.
Avivagen’s OxC-beta is a non-antibiotic alternative for livestock feeds to support immune function and promote health and growth.
The customer is a thirty-year old, family-owned business based in the Jalisco State region. The order follows a rigorous trial process where OxC-beta yielded the highest-quality milk.
The customer will receive the order in 220 kg monthly shipments beginning in September 2022.
“This new agreement represents the continued expansion of OxC-beta use within the dairy industry, a key growth market for Avivagen due to its size and positive economics,” said Kym Anthony, Avivagen’s CEO. “Mexico remains an important geographic region for us. We are excited about the potential for this first dairy order in the country to lead to others in this vital industry.”
Avivagen develops products for livestock, companion animal and human applications that support immune function and promote general health and performance.
Avivagen (VIV) is down by 5.71 per cent trading at $0.165 per share as of 9:30 am EST.
